[HTML][HTML] Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non …
LJ Hung, PC Hsu, CT Yang, CHS Kuo… - Aging (Albany …, 2024 - ncbi.nlm.nih.gov
Background: In real-world practice, most patients with lung cancer are diagnosed when they
are aged≥ 65 years. However, clinical trials tend to lack data for the elderly population …
are aged≥ 65 years. However, clinical trials tend to lack data for the elderly population …
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
G Roviello, L Zanotti, MR Cappelletti, A Gobbi… - Clinical and …, 2018 - Springer
EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib changed
dramatically the history of metastatic non-small cell lung cancer (NSCLC) harbouring EGFR …
dramatically the history of metastatic non-small cell lung cancer (NSCLC) harbouring EGFR …
[HTML][HTML] Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional …
WM Brueckl, M Reck, H Schäfer, K Neben… - Journal of Geriatric …, 2023 - Elsevier
Introduction Lung cancer is most common in older patients; despite this, older patients are
historically under-represented in clinical studies. Here we present data from GIDEON, a …
historically under-represented in clinical studies. Here we present data from GIDEON, a …
A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations
H Imai, K Kaira, K Suzuki, M Anzai, T Tsuda, T Ishizuka… - Lung Cancer, 2018 - Elsevier
Objective The efficacy and safety of afatinib in elderly patients with EGFR-mutated non-small-
cell lung cancer (NSCLC) have not been evaluated. This study aimed to assess the efficacy …
cell lung cancer (NSCLC) have not been evaluated. This study aimed to assess the efficacy …
EGFR tyrosine kinase inhibitor efficacy in older adult patients with advanced EGFR-mutated non-small-cell lung cancer: a meta-analysis and systematic review
CH Chen, DW Chou, KM Chung, HY Chang - Medicina, 2022 - mdpi.com
Background and Objectives: Lung cancer remains the most common malignancy worldwide.
As the global population ages, the prevalence of epidermal growth factor receptor (EGFR) …
As the global population ages, the prevalence of epidermal growth factor receptor (EGFR) …
A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group …
Y Minegishi, O Yamaguchi, S Sugawara, S Kuyama… - BMC cancer, 2021 - Springer
Background Lung cancer is most common among older individuals. However, polypharmacy
and comorbidities, which are also more common in older individuals, can limit treatment …
and comorbidities, which are also more common in older individuals, can limit treatment …
[HTML][HTML] Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6 …
Background Afatinib is approved in the US, Europe, and several other regions for first-line
treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell …
treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell …
Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non …
CY Chang, CY Chen, SC Chang, YC Lai… - Cancer Management …, 2021 - Taylor & Francis
Introduction Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are
standard first-line treatments for advanced EGFR-mutated non-small-cell lung cancer …
standard first-line treatments for advanced EGFR-mutated non-small-cell lung cancer …
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly
G Minuti, A D'Incecco, F Cappuzzo - Drugs & aging, 2015 - Springer
The elderly population with cancer is increasing worldwide. Currently, the median age at
lung cancer diagnosis is approximately 70 years. Clinicians are increasingly dealing with a …
lung cancer diagnosis is approximately 70 years. Clinicians are increasingly dealing with a …
Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer …
K Asami, T Koizumi, K Hirai, S Ameshima… - Clinical lung cancer, 2011 - Elsevier
Introduction Feasibility of gefitinib therapy in elderly patients with non–small-cell lung cancer
is uncertain. This phase II study aimed to investigate the efficacy and usefulness of gefitinib …
is uncertain. This phase II study aimed to investigate the efficacy and usefulness of gefitinib …
相关搜索
- effectiveness and safety elderly patients
- lung cancer elderly patients
- effectiveness and safety lung cancer
- growth factor elderly patients
- effectiveness and safety growth factor
- lung cancer growth factor
- egfr mutations elderly patients
- lung cancer afatinib treatment
- afatinib treatment elderly patients
- lung cancer egfr tyrosine
- lung cancer options in the management
- lung cancer older adults
- lung cancer meta analysis
- erlotinib treatment egfr mutation
- erlotinib treatment multicenter phase
- safety of afatinib elderly patients